Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • Amphinex: Phase II discontinued

    PCI Biotech Holding ASA (OSE:PCIB), Oslo, Norway Product: Amphinex Business: Cancer Molecular target: NA Description: Photosensitizer for photodynamic therapy (PDT) Indication: Treat head and neck cancer Endpoint: …

    Published on 6/29/2015
  • CAT-1004: Phase I/II started

    Catabasis Pharmaceuticals Inc., Cambridge, Mass. Product: CAT-1004 Business: Musculoskeletal Molecular target: Nuclear factor of kappa light polypeptide gene enhancer in B cells 1 (NF-kB) (NFKB1) (p105) (p50) …

    Published on 6/29/2015
  • Dexisometheptene mucateg: Phase II started

    Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP), New York, N.Y. Product: Dexisometheptene mucateg (TNX-201) Business: Neurology Molecular target: NA Description: Single isomer of isometheptene mucate Indication: Treat…

    Published on 6/29/2015
  • Dextenza: Phase III started

    Ocular Therapeutix Inc. (NASDAQ:OCUL), Bedford, Mass. Product: Dextenza, Dexamethasone-loaded punctum plug (OTX-DP) Business: Inflammation Molecular target: NA Description: Hydrogel-based punctum plug that delivers …

    Published on 6/29/2015
  • IV CR845: Completed Phase II enrollment

    Cara Therapeutics Inc. (NASDAQ:CARA), Shelton, Conn. Product: IV CR845 Business: Dermatology Molecular target: Kappa opioid receptor (KOR) (OPRK1) Description: Long-acting peripheral kappa opioid receptor (KOR; OPRK1) …

    Published on 6/29/2015
  • JZP-110: Phase III started

    Jazz Pharmaceuticals plc (NASDAQ:JAZZ), Dublin, Ireland SK Biopharmaceuticals Co. Ltd., Seoul, South Korea Product: JZP-110 (formerly ADX-N05) Business: Neurology Molecular target: NA Description: Phenylalanine …

    Published on 6/29/2015
  • JZP-110: Phase III started

    Jazz Pharmaceuticals plc (NASDAQ:JAZZ), Dublin, Ireland SK Biopharmaceuticals Co. Ltd., Seoul, South Korea Product: JZP-110 (formerly ADX-N05) Business: Neurology Molecular target: NA Description: Phenylalanine …

    Published on 6/29/2015
  • JZP-110: Phase III started

    Jazz Pharmaceuticals plc (NASDAQ:JAZZ), Dublin, Ireland SK Biopharmaceuticals Co. Ltd., Seoul, South Korea Product: JZP-110 (formerly ADX-N05) Business: Neurology Molecular target: NA Description: Phenylalanine …

    Published on 6/29/2015
  • Nanoplatin: Phase III ongoing

    NanoCarrier Co. Ltd. (Tokyo:4571), Kashiwa, Japan Product: Nanoplatin (NC-6004) Business: Cancer Molecular target: NA Description: Micellar nanoparticles containing cisplatin derivatives Indication: Treat locally …

    Published on 6/29/2015
  • Plecanatide: Phase III started

    Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), New York, N.Y. Product: Plecanatide (formerly SP-304) Business: Gastrointestinal Molecular target: Guanylate cyclase C (GCC) (GUCY2C) Description: Guanylate cyclase C (GCC; …

    Published on 6/29/2015
  • PVT-100: Phase IIa started

    Pivotal Therapeutics Inc. (CNSX:PVO; OTCQX:PVTTF), Woodbridge, Ontario Product: PVT-100 Business: Cardiovascular Molecular target: NA Description: Optimized long acting formulation of Omega-3 polyunsaturated fatty acids…

    Published on 6/29/2015
  • RX108: Phase I started

    Suzhou NeuPharma Co. Ltd., Suzhou, China Product: Rx108 Business: Cancer Molecular target: Na+/K+ ATPase pump Description: Small molecule Na+/K+ ATPase pump inhibitor Indication: Treat locally advanced or …

    Published on 6/29/2015
  • T-SPOT: Pivotal trial started

    Oxford Immunotec Global plc (NASDAQ:OXFD), Abingdon, U.K. Product: T-SPOT.CMV Business: Diagnostic Molecular target: NA Description: Assay that measures the strength of T cell responses to cytomegalovirus (CMV) as a …

    Published on 6/29/2015
  • AGS-003: Phase III ongoing

    Argos Therapeutics Inc. (NASDAQ:ARGS), Durham, N.C. Product: AGS-003 Business: Cancer Molecular target: Not applicable Description: Second-generation RNA-loaded autologous dendritic cell immunotherapy Indication: Treat …

    Published on 6/22/2015
  • Alprostadil: Completed Phase IIa enrollment

    Apricus Biosciences Inc. (NASDAQ:APRI), San Diego, Calif. Product: Alprostadil (RayVa) Business: Cardiovascular Molecular target: NA Description: Topical formulation of 0.42% alprostadil -- prostaglandin E1 (PGE1) -- …

    Published on 6/22/2015
  • Amantadine: Phase II started

    Adamas Pharmaceuticals Inc. (NASDAQ:ADMS), Emeryville, Calif. Product: Amantadine (ADS-5102) Business: Autoimmune Molecular target: NA Description: Oral extended-release formulation of amantadine Indication: Treat …

    Published on 6/22/2015
  • Asimadoline: Phase II started

    Tioga Pharmaceuticals Inc., San Diego, Calif. Product: Asimadoline Business: Dermatology Molecular target: Kappa opioid receptor (KOR) (OPRK1) Description: Small molecule kappa opioid receptor (KOR; OPRK1) agonist …

    Published on 6/22/2015
  • BGB-A317: Phase I started

    BeiGene Co. Ltd., Beijing, China Product: BGB-A317 Business: Cancer Molecular target: Programmed cell death 1 (PD-1) (PDCD1) (CD279) Description: Humanized anti-PD-1 mAb Indication: Treat advanced or metastatic tumors …

    Published on 6/22/2015
  • Blisibimod: Completed Phase III enrollment

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Anthera Pharmaceuticals Inc. (NASDAQ:ANTH), Hayward, Calif. Zenyaku Kogyo Co. Ltd., Tokyo, Japan Product: Blisibimod (A-623) (formerly AMG 623) Business: Autoimmune …

    Published on 6/22/2015
  • BLZ-100: Phase I started

    Blaze Bioscience Inc., Seattle, Wash. Product: BLZ-100 (formerly CyTP 007) Business: Diagnostic Molecular target: NA Description: Variant of the peptide chlorotoxin, derived from scorpion venom, combined with a near-…

    Published on 6/22/2015
  • Cannabidiol: Phase III started

    GW Pharmaceuticals plc (LSE:GWP; NASDAQ:GWPH), Salisbury, U.K. Product: Cannabidiol (Epidiolex) Business: Neurology Molecular target: Cannabinoid receptors Description: Oral liquid formulation of cannabidiol, a …

    Published on 6/22/2015
  • CollaRx gentamicin topical: Phase III started

    Innocoll AG (NASDAQ:INNL), Athlone, Ireland Product: CollaRx gentamicin topical, Cogenzia Business: Infectious Molecular target: Ribosomal 30S subunit Description: Topical bioresorbable collagen sponge with gentamicin …

    Published on 6/22/2015
  • Eltoprazine: Phase IIb started

    Amarantus BioScience Holdings Inc. (OTCQB:AMBS), San Francisco, Calif. PsychoGenics Inc., Tarrytown, N.Y. Product: Eltoprazine Business: Neurology Molecular target: Serotonin (5-HT1A) receptor; Serotonin (5-HT1B) …

    Published on 6/22/2015
  • Encenicline: Completed Phase III enrollment

    Forum Pharmaceuticals Inc., Waltham, Mass. Bayer AG (Xetra:BAYN), Leverkusen, Germany Product: Encenicline (EVP-6124, MT-4666) Business: Neurology Molecular target: Nicotinic acetylcholine receptor alpha 7 (CHRNA7) …

    Published on 6/22/2015
  • GKI-399: Phase II started

    vTv Therapeutics LLC, High Point, N.C. Product: GKI-399, TTP399 Business: Endocrine/Metabolic Molecular target: Glucokinase (GCK) (GK) Description: Liver-selective glucokinase (GCK; GK) activator Indication: Treat Type …

    Published on 6/22/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993